KER-050

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

Near Add Your Location

Sorting 5 by

Center of Excellence

  • Accepting patients

Center of Excellence

  • Accepting patients

Center of Excellence

  • Accepting patients

Center of Excellence

UPMC Hillman Cancer Center
University of Pittsburgh Medical Center (UPMC)
Pittsburgh, PA
  • Not yet accepting
Karmanos Cancer Institute
McLaren Greater Lansing
Lansing, MI
  • Not yet accepting
518 hidden based on your filters. Show All

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.